Focus on Osteosclerotic Progression in Primary Myelofibrosis
Authors:
- Mariarita SpampinatoMSMariarita Spampinato
- Cesarina GiallongoCGCesarina Giallongo
- Alessandra RomanoAlessandra Romano
- Lucia LonghitanoLLLucia Longhitano
- Enrico La SpinaESEnrico La Spina
- Roberto AvolaRARoberto Avola
- Grazia ScanduraGSGrazia Scandura
- Ilaria DulcamareIDIlaria Dulcamare
- Vincenzo BramantiVincenzo Bramanti
- Michelino Di RosaMichelino Di Rosa
- Nunzio VicarioNunzio Vicario
- Rosalba ParentiRosalba Parenti
Open Access
- 19 January 2021
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 11 (1) , 122
Abstract
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by hematopoietic stem-cell-derived clonal proliferation, leading to bone marrow (BM) fibrosis. Hematopoiesis alterations are closely associated with modifications of the BM microenvironment, characterized by defective interactions between vascular and endosteal niches. As such, neoangiogenesis, megakaryocytes hyperplasia and extensive bone marrow fibrosis, followed by osteosclerosis and bone damage, are the most relevant consequences of PMF. Moreover, bone tissue deposition, together with progressive fibrosis, represents crucial mechanisms of disabilities in patients. Although the underlying mechanisms of bone damage observed in PMF are still unclear, the involvement of cytokines, growth factors and bone marrow microenvironment resident cells have been linked to disease progression. Herein, we focused on the role of megakaryocytes and their alterations, associated with cytokines and chemokines release, in modulating functions of most of the bone marrow cell populations and in creating a complex network where impaired signaling strongly contributes to progression and disabilities.Keywords
This publication has 130 references indexed in Scilit:
- The hematopoietic stem cell niche—home for friend and foe?Cytometry Part B: Clinical Cytometry, 2012
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic ExperienceMayo Clinic Proceedings, 2012
- How I treat splenomegaly in myelofibrosisBlood Cancer Journal, 2011
- Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in miceJournal of Experimental Medicine, 2011
- Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell nicheJournal of Experimental Medicine, 2011
- Engraftment and Reconstitution of Hematopoiesis Is Dependent on VEGFR2-Mediated Regeneration of Sinusoidal Endothelial CellsCell Stem Cell, 2009
- Functions of RANKL/RANK/OPG in bone modeling and remodelingArchives of Biochemistry and Biophysics, 2008
- Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosisBlood, 2007
- Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systemsNature Reviews Immunology, 2007
- The stem cell niches in boneJournal of Clinical Investigation, 2006